Şunu aradınız:: melatonin (Maltaca - İngilizce)

kull pillola fiha 2 mg melatonin.
each tablet contains 2 mg melatonin.

is-sustanza attiva hi melatonin.
the active substance is melatonin.

riċetturi agonisti ta ’ melatonin, kodiċi atc:
melatonin receptor agonists, atc code:

circadin hu mediċina li fiha s-sustanza attiva melatonin.
circadin is a medicine that contains the active substance melatonin.

għandu jkun hemm attenzjoni meta melatonin jingħata lil dawn il-pazjenti.
caution should be used when melatonin is administered to such patients.

circadin 2 mg pilloli li jerħu l-mediċina bil-mod melatonin
circadin 2 mg prolonged-release tablets melatonin

kull pillola li terħi l-mediċina bil-mod fiha 2 mg melatonin.
each prolonged-release tablet contains 2 mg melatonin.

f’ konċentrazzjonijiet supra- terapewtiċi kien osservat li melatonin jinduċi cyp3a.
melatonin has been observed to induce cyp3a in vitro at supra-therapeutic concentrations.

anzjani il- metaboliżmu ta ’ melatonin huwa magħruf li jonqos bl- età.
elderly melatonin metabolism is known to decline with age.

għal melatonin m’hemmx tagħrif kliniku dwar l-użu waqt it-tqala.
for melatonin, no clinical data on exposed pregnancies are available.

l-anzjani ġieli jipproduċu inqas melatonin, u dan iwassal għall-insomnja.
older people may produce less melatonin, leading to the development of insomnia.

għalhekk, it- treddigħ mhux rakkomandat f’ nisa li qed jiġu kkurati b’ melatonin.
therefore, breast-feeding is not recommended in women under treatment with melatonin.

circadin m' għandux jintuża minn persuni li jkunu allerġiċi għal melatonin jew għal xi sustanza oħra tiegħu.
circadin should not be used in people who may be hypersensitive (allergic) to melatonin or any of the other ingredients.

melatonin huwa ormon naturali li jiġi prodott mill-glandola pinejali u huwa relata strutturalment ma’ serotonin.
melatonin is a naturally occurring hormone produced by the pineal gland and is structurally related to serotonin.

din is- sejba hi kompatibbli mal-half-life qasira ta’ melatonin fil-bniedem.
this finding is compatible with the short half-life of melatonin in humans.

ir-rabta in vitro ta’ melatonin mal-proteini fil-plażma hi madwar 60%.
the in vitro plasma protein binding of melatonin is approximately 60%.

distribuzzjoni ir- rabta in vitro ta ’ melatonin mal- proteini fil- plażma hi madwar 60%.
distribution the in vitro plasma protein binding of melatonin is approximately 60%.

fiżjoloġikament, ir-reħa ta’ melatonin tiżdied hekk kif jibda’ jidlam, tilħaq il-quċċata ma’
physiologically, melatonin secretion increases soon after the onset of darkness, peaks at

melatonin huwa assoċjat mal-kontroll tar-ritmi ċirkadjani u marbut maċ-ċiklu tad-dawl u tad-dlam.
melatonin is associated with the control of circadian rhythms and entrainment to the light-dark cycle.

melatonin endoġenu kien imkejjel fil-ħalib tas-sider tal-bniedem u għalhekk probabbilment melatonin exoġenu jintreħa fil-ħalib uman.
endogenous melatonin was measured in human breast milk thus exogenous melatonin is probably secreted into human milk.